OTCQB

Sow Good Appoints Brendon Fischer as Interim Chief Financial Officer

Retrieved on: 
Tuesday, April 2, 2024
Dallas–Fort Worth metroplex, Moses Austin, CFO, Business, Business administration, Knowledge, Research, University, Food, CFA, McCombs School of Business, Sow, OTCQB

IRVING, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Sow Good Inc. (OTCQB: SOWG) ("Sow Good" or “the Company”), a trailblazer in the freeze dried candy and treat industry, announced today that Brendon Fischer has been appointed as the Company’s interim chief financial officer (CFO), following the resignation of the Company’s former CFO, Keith Terreri.

Key Points: 
  • IRVING, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Sow Good Inc. (OTCQB: SOWG) ("Sow Good" or “the Company”), a trailblazer in the freeze dried candy and treat industry, announced today that Brendon Fischer has been appointed as the Company’s interim chief financial officer (CFO), following the resignation of the Company’s former CFO, Keith Terreri.
  • Fischer first joined the Sow Good team in June 2023, bringing over 20 years of leadership experience in financial analysis, shareholder communications, and regulatory compliance with public and private companies.
  • Before joining Sow Good, Fischer served as the chief investment officer, managing director, and chief compliance officer of Fischer Capital Management, an investment advisory firm he founded in 2018.
  • We would like to thank Keith for his time at Sow Good and wish him all the best in his future endeavors.”

Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, April 2, 2024
Uterus, Gynaecology, Longevity, Reproductive Sciences, Patient, Collaboration, University, EMA, MD, European Medicines Agency, European, PIPE, Esophageal atresia, Yale school, OTCQB, Cryptocurrency

The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.

Key Points: 
  • The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.
  • Company’s subsidiary in Hong Kong launched its longevity product business in Asia, generating more than $100,000 in 2023 sales.
  • Entered into securities purchase agreements with accredited investors for a $6 million private investment in public equity (PIPE) financing.
  • Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”

Retrieved on: 
Tuesday, April 2, 2024
Absorption, Açaí palm, Hemp, D3, UST, Business development, CBD, Human, Collection, Marketing, Plant, Commonwealth, Wellness, OTCQB, Animal, Agriculture, Pharmaceutical industry

CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud’s Health & Wellness consumer packaged goods subsidiary (“Uncle Bud’s”) has experienced significant sales activity in its revolutionary nanoemulsified CBD product offered in the initial launch of its highly touted “Premium Collection” of UltraShear™ processed nanoemulsion products. Click here for more info on Uncle Bud's Premium Collection.

Key Points: 
  • Click here for more info on Uncle Bud's Premium Collection.
  • The Premium Collection was an immediate success, highlighted by the unprecedented response to its initial product in the Collection - the CBD Body Revive Spray with 1200mg of Nano-CBD.
  • “Uncle Bud’s newly launched Nano-CBD Body Revive Spray, an innovative, all plant-based, organic, highly bioavailable flagship product processed using PBIO’s UltraShear platform, captured an impressive 30% conversion of Uncle Bud’s total CBD Revive Spray product revenue in March alone,” commented John Hollister, PBIO’s Director of Sales and Marketing.
  • This achievement enables PBIO to develop, manufacture, market, and sell UST-processed products into the rapidly expanding CBD marketplace.

Dalrada Financial Corporation Announces Heat Pump Product Expansion, Enters Home and Residential Heat Pump Market

Retrieved on: 
Tuesday, April 2, 2024
IRS, Heat, SAN, Air conditioning, Climate, Ventilation, Research, News, Carbon, HVAC, OTCQB, Internal Revenue Service, Average revenue per user, Renewable energy

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada,” “the Company”), announced today the formation of Dalrada Home Inc., a wholly-owned subsidiary, to enter the booming home heat pump market by offering high-efficiency, cost-saving heat pumps specifically designed for residential use and hinting at further development.

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO , “Dalrada,” “the Company”), announced today the formation of Dalrada Home Inc. , a wholly-owned subsidiary, to enter the booming home heat pump market by offering high-efficiency, cost-saving heat pumps specifically designed for residential use and hinting at further development.
  • Dalrada’s range of impressive home heat pumps will fit the vast majority of American single-family homes from 850 square feet and above.
  • The expected product lineup will be announced in three to four weeks, with priority shipping available in approximately four weeks.
  • According to a 2023 report, the U.S. residential heat pump market was valued at over $13 billion , and is expected to reach nearly $30 billion by 2032.

BioCorRx Reports Business Update for 2023

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Substance abuse, Bupropion, CFO, Risk, Public, OUD, Research, Security (finance), Opioid use disorder, NIH, Naltrexone, Bangladesh Technical Education Board, MUD, OTCQB, Pharmaceutical industry

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD).
  • We successfully decreased our total operating expenses by over $1.0 million for the year ending December 31, 2023, compared to the previous year.
  • Overall, we are optimistic about the business outlook and look forward to continuing to develop medicines.

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Tuesday, April 2, 2024
Hospital, TMX Group, Teaching hospital, Phase, OTCQB, Liver

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey.
  • The trial now has a total of seven clinical sites across Turkey and Canada.

Nowigence Inc. Invited to Present at Museum Association of New York on the 9th of April 2024

Retrieved on: 
Tuesday, April 2, 2024
Science, Research, Origin, Food, AI, Doctor of Philosophy, Exhibition, Artifact, OTCQB, Archive

Ground to Gourmet blends history, science, and art while exploring the deep culinary heritage of New York State.

Key Points: 
  • Ground to Gourmet blends history, science, and art while exploring the deep culinary heritage of New York State.
  • With interactive displays, artifacts and art visitors are transported on a journey through the fascinating origins of the food we cherish.
  • Gina C. Gould, PhD, President, miSci, said, “Helping visitors meaningfully interact with the breadth of information that goes into creating an exhibition is a perennial challenge for the museum field.
  • The AI Co-Pilot from Nowigence – Lille.ai – found meaningful connections in our research upon uploading our archives into Lille, that we didn’t know existed.

Demand Climbs as Global Lithium Market Size Expected to Reach $9.03 Billion in 2024

Retrieved on: 
Tuesday, April 2, 2024
Well, Dorado, USGS, Duke University, Transport, CPG, Commerce, Investment, USD, Pontifical university, LSS, Corporate law, EVS, General counsel, PALM, Bureau, Demonstration, Operation, Calendar, OTCQB, HP, Electricity, Ministry of home affairs, Organization, Georgetown University, Allkem, News, Acquisition, National instrument, TSX, Demonstration plant, SLI, Military, Mining, LAAC, Growth, MP3, Livent, Mineral, Behavior, Pan-American, Lithium

A report from Grand View Research said that revenues will reach USD 9.03 billion in 2024 and the Increasing investments in EV manufacturing across the world are expected to positively influence the growth of the lithium market over the forecast period (2024 to 2030).

Key Points: 
  • A report from Grand View Research said that revenues will reach USD 9.03 billion in 2024 and the Increasing investments in EV manufacturing across the world are expected to positively influence the growth of the lithium market over the forecast period (2024 to 2030).
  • In 2018, Interior Department listed lithium as a critical mineral, which paced up the mine permitting process.
  • Grand View Research continued: “The market is characterized by a high degree of innovation to optimize both the manufacturing process, and also obtain high purity lithium.
  • Players have invested in R&D heavily to optimize the usage of lithium in high-growth end use segments such as electric vehicles.

Global Uranium Production to Increase as Prices Are Expected to Hit a 15 Year High

Retrieved on: 
Tuesday, April 2, 2024
Triple, CPS, Appaloosa, International Financial Reporting Standards, Transport, OTCQX, Party, Westinghouse, Count, Technical, International, PALM, PLS, GlobalData, Fertility, Stallion, Glacier Media, Climate change, COP28, STUD, Ice, OTCQB, FCU, Athabasca Basin, News, Handgun holster, Radioactive decay, TSX, NXE, NexGen, Mining, Conference, Growth, Conference of the Parties, Fission, FUU, BGO, Uranium mining

It added: "Kazakhstan is expected to deliver the highest uranium production growth in 2024, GlobalData says, driven by the planned higher output from the country’s largest uranium producer Kazatomprom.

Key Points: 
  • It added: "Kazakhstan is expected to deliver the highest uranium production growth in 2024, GlobalData says, driven by the planned higher output from the country’s largest uranium producer Kazatomprom.
  • The continuous ramp-up of Canada’s McArthur River uranium mine will also contribute to the global increase, it adds.
  • Despite a 5.1% dip in output in 2023 due to planned lower production from Kazatomprom, its output is expected to recover in 2024, with forecast production of 23.2kt.
  • It continued: “Meanwhile, global uranium production in 2024 will be further bolstered by continuous ramp-up of Canada’s McArthur River, which is aiming to produce 6.9kt of uranium (8.2kt of U3O8) for 2024.

HealthLynked Announces Fourth Quarter and Full Year 2023 Results Highlighted by 70% Reduction in Net Loss for Q4

Retrieved on: 
Tuesday, April 2, 2024
Commitment, Growth, IBN, CFO, Physician, Patient, Lead, Sale, Way, Retirement, ARI, OTCQB, Core, Health, Pharmaceutical industry

With strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.

Key Points: 
  • With strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.
  • Dramatic Net Loss Reduction: A significant decrease in net loss to $1.01 million in 2023 from $8.82 million in 2022 illustrates the positive impact of our strategic divestitures, operational efficiencies, and profit stabilization despite temporary staffing changes.
  • Strategic Initiatives Lead to Reduced Operating Loss: A 73% reduction in operating loss to $1.11 million in Q4 2023, demonstrating our resilience and strategic focus during a period of staffing transition.
  • George O'Leary, CFO of HealthLynked, added, "Our strategic decisions throughout 2023 have laid a solid groundwork for growth.